George Demetri, MDDirector, Sarcoma Center
*Explain the mechanistic rationale for using TRK inhibitors to treat certain cancers, such as those containing NTRK fusions.
*Describe pivotal clinical trials surrounding the use of TRK inhibition for the treatment of cancers with NTRK fusions.
*Summarize key considerations in designing treatment plans for patients with cancers containing NTRK fusions, with an emphasis on the therapeutic role of TRK inhibition in management.
Traditionally, cancer therapies were designed and then approved for the treatment of specific tumor types, for example, breast cancer or lung cancer. Now, in recent years, cancer therapies targeting specific molecular alterations have gained momentum in clinical research and are slowly entering the therapeutic landscape.
TRK inhibitors are one such example, which may be used to treat cancers harboring NTRK fusions. Two such agents have already been approved by the FDA, including larotrectinib and entrectinib. These agents can be used as treatment across multiple tumor types, for both adult and pediatric patients, given that cancer harbors this molecular alteration. In addition, the role of TRK inhibitors in treating tumors with NTRK fusions is being further investigated, with new developments expected on the horizon. For example, next-generation TRK inhibitors including selitrectinib and repotrectinib may address challenges with resistance that are arising with first-generation TRK inhibitors.
Here, we present a short but concise learning module that provides a high-level overview of the use of TRK inhibition to treat cancers harboring NTRK fusions, offer expert strategies, clinical pearls, and best practice recommendations.
The content for this program has been independently developed by Clinical Care Solutions.